Uncommon Therapeutics
Uncommon Therapeutics is a YC Winter 2025 (W25) company. Based in San Francisco, CA, USA. Team of 2.
About Uncommon Therapeutics
Summary
Uncommon Therapeutics develops therapeutics targeting the root cause of rare genetic diseases, starting with Rett Syndrome, a neurodevelopmental condition affecting one in ten thousand girls. The company applies a polytherapy strategy, validating multiple drug modalities in disease-relevant models to advance a pipeline that individually improves patient outcomes and in combination aims to deliver a cure. This work replaces the standard single-target approach with a coordinated multi-drug design built around deep, firsthand disease expertise.
From the Y Combinator listing
A Disease Focused Biotech, Building Multiple Billion Dollar Drugs
Our founder Noah, an experienced tech entrepreneur, was directly impacted by a severe genetic disease when his daughter was diagnosed with Rett Syndrome, a disease that afflicts 1 in 10,000 girls. Using an innovative polytherapy strategy, we’ve successfully improved her quality of life, and have designed new therapeutics that each could be worth billions and together could deliver a cure.
Facts
- Healthcare / Healthcare -> Therapeutics
- San Francisco, CA, USA
- 2
- Active
- Early
Founders (2)
- Noah Auerhahn
- Ryan Lim
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works